GLP1R and obesity disorder: Tirzepatide is a once‐weekly dual glucose‐dependent insulinotropic polypeptide (GIP) and GLP‐1 receptor agonist, approved for the treatment of adults with type 2 diabetes (T2D), for weight management in adults with obesity or overweight with at least one weight‐related comorbid condition, and for obstructive sleep apnoea in adults with obesity.5, 6, 7